Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C20H23F4N3O |
Molar mass | 397.418 g·mol−1 |
3D model (JSmol) | |
| |
|
CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]
See also
References
- ↑ Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Yamaguchi T, et al. (February 2008). "Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action". Bioorganic & Medicinal Chemistry. 16 (3): 1111–24. doi:10.1016/j.bmc.2007.10.087. PMID 18006322.
- ↑ Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y, et al. (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6299–304. doi:10.1016/j.bmcl.2007.09.004. PMID 17884496.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.